Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France Relaxes Stance On Biosimilar Switching

This article was originally published in SRA

Executive Summary

The French regulatory agency ANSM has relaxed its stance on biosimilar interchangeability to state that while in principle patients should preferably not be switched between a reference drug and a biosimilar during their course of treatment, this can be done provided the patient agrees and their treatment is closely monitored1.

You may also be interested in...



French Govt Calls For 70% Biosimilar Prescribing Rate; Substitution Groups Published

Moves are under way in France to give the biosimilars market a shot in the arm by setting a 70% target for initial prescribing rates and encouraging pharmacist substitution through the creation of similar biological medicine groups.

French Govt Calls For 70% Biosimilar Prescribing Rate; Substitution Groups Published

Moves are under way in France to give the biosimilars market a shot in the arm by setting a 70% target for initial prescribing rates and encouraging pharmacist substitution through the creation of similar biological medicine groups.

France 2017: More Price Cuts, Rebates, Generics and Biosimilars, And A New Innovation Fund

The French pharmaceutical industry has reacted angrily to some of the provisions in the 2017 social security financing bill, arguing that the measures are inappropriate and that the government is taking a purely financial approach to addressing the costs of healthcare products, rather than taking wider public health considerations into account.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel